Keiichi Enjyoji

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness
    Norikatsu Mizumoto
    Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Nat Med 8:358-65. 2002
  2. pmc Deletion of cd39/entpd1 results in hepatic insulin resistance
    Keiichi Enjyoji
    Liver Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Diabetes 57:2311-20. 2008
  3. pmc Regulated catalysis of extracellular nucleotides by vascular CD39/ENTPD1 is required for liver regeneration
    Guido Beldi
    Transplant and Liver Centers, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, Massachusetts 02215, USA
    Gastroenterology 135:1751-60. 2008
  4. pmc Natural killer T cell dysfunction in CD39-null mice protects against concanavalin A-induced hepatitis
    Guido Beldi
    Liver and Transplantation Centers, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Hepatology 48:841-52. 2008
  5. pmc From the Cover: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease
    David J Friedman
    Renal Division and Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard University, 330 Brookline Avenue, Boston, MA 02215, USA
    Proc Natl Acad Sci U S A 106:16788-93. 2009
  6. pmc Deletion of CD39 on natural killer cells attenuates hepatic ischemia/reperfusion injury in mice
    Guido Beldi
    Department of Medicine and Surgery, Liver Center and Transplantation Institute, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Hepatology 51:1702-11. 2010
  7. pmc CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice
    Xiaofeng Sun
    Department of Medicine, Transplantation Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Gastroenterology 139:1030-40. 2010
  8. doi request reprint Variable impact of CD39 in experimental murine colitis
    Beat M Künzli
    Transplant Institute and Gastroenterology Division, Beth Israel Deaconess Medical Centre Harvard Medical School, Harvard University, Boston, MA 02215, USA
    Dig Dis Sci 56:1393-403. 2011
  9. pmc Disordered pancreatic inflammatory responses and inhibition of fibrosis in CD39-null mice
    Beat M Künzli
    Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, Massachusetts, USA
    Gastroenterology 134:292-305. 2008
  10. pmc Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null mice
    Shaun W Jackson
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Am J Pathol 171:1395-404. 2007

Collaborators

Detail Information

Publications26

  1. ncbi request reprint CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness
    Norikatsu Mizumoto
    Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Nat Med 8:358-65. 2002
    ....
  2. pmc Deletion of cd39/entpd1 results in hepatic insulin resistance
    Keiichi Enjyoji
    Liver Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Diabetes 57:2311-20. 2008
    ..CD39/ENTPD1 is the dominant vascular and immune cell ectoenzyme that hydrolyzes extracellular nucleotides to regulate purinergic signaling...
  3. pmc Regulated catalysis of extracellular nucleotides by vascular CD39/ENTPD1 is required for liver regeneration
    Guido Beldi
    Transplant and Liver Centers, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, Massachusetts 02215, USA
    Gastroenterology 135:1751-60. 2008
    ..We aimed to determine the effects of the vascular ectonucleotidase CD39 on sinusoidal endothelial cell responses following partial hepatectomy and to dissect purinergic and growth factor interactions in this model...
  4. pmc Natural killer T cell dysfunction in CD39-null mice protects against concanavalin A-induced hepatitis
    Guido Beldi
    Liver and Transplantation Centers, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Hepatology 48:841-52. 2008
    ..Hepatic NKT cells express most P2X and P2Y receptors; exceptions include P2X3 and P2Y11. Heightened levels of apoptosis of CD39 null NKT cells in vivo and in vitro appear to be driven by unimpeded activation of the P2X7 receptor...
  5. pmc From the Cover: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease
    David J Friedman
    Renal Division and Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard University, 330 Brookline Avenue, Boston, MA 02215, USA
    Proc Natl Acad Sci U S A 106:16788-93. 2009
    ..005-0.0006). Our data indicate that CD39 deficiency exacerbates murine colitis and suggest that CD39 polymorphisms are associated with inflammatory bowel disease in humans...
  6. pmc Deletion of CD39 on natural killer cells attenuates hepatic ischemia/reperfusion injury in mice
    Guido Beldi
    Department of Medicine and Surgery, Liver Center and Transplantation Institute, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Hepatology 51:1702-11. 2010
    ....
  7. pmc CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice
    Xiaofeng Sun
    Department of Medicine, Transplantation Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Gastroenterology 139:1030-40. 2010
    ..In this study, we have examined the effect of CD39 expression by Tregs on effector immune cell responses to hepatic metastases in vivo...
  8. doi request reprint Variable impact of CD39 in experimental murine colitis
    Beat M Künzli
    Transplant Institute and Gastroenterology Division, Beth Israel Deaconess Medical Centre Harvard Medical School, Harvard University, Boston, MA 02215, USA
    Dig Dis Sci 56:1393-403. 2011
    ..Genetic polymorphisms of CD39 have been linked to Crohn's disease while gene deletion in mice exacerbates dextran sodium sulphate-induced colitis...
  9. pmc Disordered pancreatic inflammatory responses and inhibition of fibrosis in CD39-null mice
    Beat M Künzli
    Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, Massachusetts, USA
    Gastroenterology 134:292-305. 2008
    ..Because the role of extracellular nucleotides and CD39 in mediating inflammation and fibrosis are understood poorly, we studied the impact of CD39 gene deletion in a model of pancreatic disease...
  10. pmc Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null mice
    Shaun W Jackson
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Am J Pathol 171:1395-404. 2007
    ..Our data indicate novel links between CD39/ENTPD1, extracellular nucleotide-mediated signaling, and vascular endothelial cell integrin function that impact on angiogenesis and tumor growth...
  11. pmc Functional ENTPD1 polymorphisms in African Americans with diabetes and end-stage renal disease
    David J Friedman
    Renal Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Diabetes 58:999-1006. 2009
    ..The vascular ectonucleotidase ENTPD1 protects against renal injury and modulates glucose homeostasis in mouse models. We sought to determine whether human variation in ENTPD1 influences predisposition to diabetes or diabetic nephropathy...
  12. pmc The role of purinergic signaling in the liver and in transplantation: effects of extracellular nucleotides on hepatic graft vascular injury, rejection and metabolism
    Guido Beldi
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, MA 02215, USA
    Front Biosci 13:2588-603. 2008
    ....
  13. pmc Tob1 is a constitutively expressed repressor of liver regeneration
    Karen J Ho
    Department of Surgery, The Transplant Institute, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Exp Med 207:1197-208. 2010
    ..We provide direct evidence that levels of an inhibitory factor control the rate of liver regeneration, and we identify Tob1 as a crucial check point molecule that modulates the expression and activity of cell cycle proteins...
  14. ncbi request reprint The vascular ectonucleotidase ENTPD1 is a novel renoprotective factor in diabetic nephropathy
    David J Friedman
    Renal Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Diabetes 56:2371-9. 2007
    ..We conclude that ENTPD1 is a vascular protective factor in diabetic nephropathy that modulates glomerular inflammation and thromboregulation...
  15. ncbi request reprint Ecto-nucleotidases of the CD39/NTPDase family modulate platelet activation and thrombus formation: Potential as therapeutic targets
    Ben Atkinson
    Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    Blood Cells Mol Dis 36:217-22. 2006
    ..Future clinical applications will involve the development of new therapeutic strategies to various inflammatory vascular diseases and in transplantation...
  16. ncbi request reprint Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation
    Simon C Robson
    Vascular Biology and Transplantation Centers, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Research North, 99 Brookline Avenue, Boston, MA 02215, USA
    Semin Thromb Hemost 31:217-33. 2005
    ..Administration of soluble CD39 or targeted expression may have future therapeutic application in transplantation-associated and other vascular diseases...
  17. pmc Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer
    Beat M Künzli
    Liver and Transplantation Centers, Beth Israel Deaconess Medical Center, Harvard University, Boston, USA
    Purinergic Signal 7:231-41. 2011
    ..Our studies also suggest potential roles for purinergic-based therapies in clinical CRC...
  18. pmc Liver damage and systemic inflammatory responses are exacerbated by the genetic deletion of CD39 in total hepatic ischemia
    Xiaofeng Sun
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 3, Blackfan Circle, Boston, MA, 02115, USA
    Purinergic Signal 7:427-34. 2011
    ..We conclude that CD39 is protective in hepatic IRI preventing local injury and systemic inflammation in an adenosine dependent manner. Our data indicate that vascular CD39 expression has an essential protective role in hepatic IRI...
  19. pmc Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors
    Holger K Eltzschig
    Center for Experimental Therapeutics and Reperfusion Injury, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    J Exp Med 198:783-96. 2003
    ..Taken together, these results demonstrate transcription coordination of adenine nucleotide and nucleoside signaling at the vascular interface during hypoxia...
  20. pmc P2X7 Integrates PI3K/AKT and AMPK-PRAS40-mTOR Signaling Pathways to Mediate Tumor Cell Death
    Shu Bian
    Department of Gastroenterology, Provincial Hospital affiliated to Shandong University, Jinan, People s Republic of China Department of Medicine, Transplant Institute, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 8:e60184. 2013
    ..CONCLUSIONS: Our study defines novel molecular mechanisms underpinning the antitumor actions of P2X7 and provides a further rationale for purine-based drugs in targeted cancer therapy...
  21. pmc Vascular smooth muscle cell expression of ectonucleotidase CD39 (ENTPD1) is required for neointimal formation in mice
    Amir Behdad
    Transplantation Institute and Liver Center, CLS 612, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    Purinergic Signal 5:335-42. 2009
    ..Cd39 is the dominant ectonucleotidase expressed by VSMC. Deletion of Cd39 in mice results in decreased neointimal formation after vascular injury and is associated with impaired VSMC migration responses in vitro...
  22. pmc Normal levels of anticoagulant heparan sulfate are not essential for normal hemostasis
    Sassan HajMohammadi
    Section of Cardiology, Department of Medicine, Dartmouth Medical School, Hanover, New Hampshire, USA
    J Clin Invest 111:989-99. 2003
    ..Instead, 3-OST-1-deficient mice exhibited unanticipated phenotypes suggesting that HS(act) or additional 3-OST-1-derived structures may serve alternate biologic roles...
  23. doi request reprint Tubuloglomerular feedback and renin secretion in NTPDase1/CD39-deficient mice
    Mona Oppermann
    National Institute of Digestive and Diabetes and Kidney Diseases, National Institute of Health, 10 Center Drive MSC 1370, Bethesda, MD 20892, USA
    Am J Physiol Renal Physiol 294:F965-70. 2008
    ....
  24. ncbi request reprint The ectonucleotidase cd39/ENTPDase1 modulates purinergic-mediated microglial migration
    Katrin Färber
    Cellular Neuroscience, Max Delbruck Center for Molecular Medicine, Berlin, Germany
    Glia 56:331-41. 2008
    ..We conclude that the co-stimulation of purinergic and adenosine receptors is a requirement for microglial migration and that the expression of cd39 controls the ATP/adenosine balance...
  25. ncbi request reprint Beneficial effects of CD39/ecto-nucleoside triphosphate diphosphohydrolase-1 in murine intestinal ischemia-reperfusion injury
    Olaf Guckelberger
    Department of Visceral and Transplantation Surgery, Charite Campus Virchow Clinic, Humboldt University, Berlin, Germany
    Thromb Haemost 91:576-86. 2004
    ..The potential of NTPDases to maintain vascular integrity suggests potential pharmacological benefit of these agents in mesenteric ischemic injury...
  26. ncbi request reprint Tissue factor pathway inhibitor gene delivery using HVJ-AVE liposomes markedly reduces restenosis in atherosclerotic arteries
    Xinhua Yin
    Department of Pathology, National Cardiovascular Center, 5 7 1 Fujishiro dai, Suita City, Osaka, Japan
    Cardiovasc Res 56:454-63. 2002
    ..We also evaluated the safety of the novel gene therapeutic strategy to prevent restenosis...